• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aspira Women's Health Inc. (Amendment)

    2/16/22 12:28:00 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $AWH alert in real time by email
    SC 13G/A 1 d239420dsc13ga.htm AMENDMENT NO. 3 Amendment No. 3

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (c), AND (d)

    (Amendment No. 3)*

     

     

    Aspira Women’s Health Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    04537Y109

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    Schedule 13G    Page 2 of 10 Pages

     

    CUSIP NO. 04537Y109

      

     

      1.    

      Names of Reporting Persons

      I.R.S. Identification Nos. of above persons (entities only)

     

      Seamark Capital, L.P.     23-3074461

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware, United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      5,558,966 shares

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      5,558,966 shares

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      Seamark Capital, L.P. – 5,558,966 shares

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)*

     

      5.0 % Seamark Capital, L.P.

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    *

    Seamark Capital, L.P. is the sole Investment Advisor to the Seamark Fund, L.P., a passive investment partnership vehicle. Messrs. Fraser and Harrington are Co-Managing Partners of Seamark Capital, L.P., and are sole Partners of Seamark Partners, L.P., the General Partner of Seamark Capital, L.P. Reference is made to Item 4 of this Schedule 13G.


    Schedule 13G    Page 3 of 10 Pages

     

    CUSIP NO. 04537Y109

      

     

      1.    

      Names of Reporting Persons

      I.R.S. Identification Nos. of above persons (entities only)

     

      John D. Fraser

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Pennsylvania, United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      525,196 shares

       6.   

      Shared Voting Power

     

      5,558,966 shares

       7.   

      Sole Dispositive Power

     

      525,196 shares

       8.   

      Shared Dispositive Power

     

      5,558,966 shares

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      John D. Fraser    6,084,162 shares

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)*

     

      5.4% (including 0.5% by Mr. Fraser individually)

    12.  

      Type of Reporting Person (See Instructions)

     

      IN

     

    *

    John D. Fraser is Co-Managing Partner of Seamark Capital, L.P. Reference is made to Item 4 of this Schedule 13G.


    Schedule 13G    Page 4

     

    CUSIP NO. 04537Y109

      

     

      1.    

      Names of Reporting Persons

      I.R.S. Identification Nos. of above persons (entities only)

     

      David T. Harrington

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Pennsylvania

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      930,000 shares

       6.   

      Shared Voting Power

     

      5,558,966 shares

       7.   

      Sole Dispositive Power

     

      930,000 shares

       8.   

      Shared Dispositive Power

     

      5,558,966 shares

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person*

     

      David T. Harrington    6,488,966 shares

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.8 % (including 0.8% by Mr. Harrington individually)

    12.  

      Type of Reporting Person (See Instructions)

     

      IN

     

    *

    David T. Harrington is Co-Managing Partner of Seamark Capital, L.P. Reference is made to Item 4 of this Schedule 13G.


    Schedule 13G    Page 5

     

    CUSIP NO. 04537Y109

      

     

    Item 1.(a)

    Name of Issuer:

    Aspira Women’s Health Inc.

     

    Item 1.(b)

    Address of Issuer’s Principal Executive Offices:

    12117 Bee Caves Road

    Building Three

    Suite 100

    Austin, TX 78738

    United States

     

    Item 2.(a)

    Name of Person Filing:

     

      (1)

    Seamark Capital, L.P.

      (2)

    John D. Fraser

      (3)

    David T. Harrington

     

    Item 2.(b)

    Address of Principal Business Office or, if none, Residence:

     

      (1)

    223 Wilmington West Chester Pike, Suite 115

    Chadds Ford, PA 19317

      (2)

    223 Wilmington West Chester Pike, Suite 115

    Chadds Ford, PA 19317

      (3)

    223 Wilmington West Chester Pike, Suite 115

    Chadds Ford, PA 19317

     

    Item 2.(c)

    Citizenship:

     

      (1)

    Delaware

      (2)

    Pennsylvania

      (3)

    Pennsylvania

     

    Item 2.(d)

    Title of Class of Securities:

    Common Stock, par value $0.001 per share

     

    Item 2.(e)

    CUSIP Number:

    04537Y109


    Schedule 13G    Page 6

     

    CUSIP NO. 04537Y109

      

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-(b)(1)(ii)(F).
    (g)    ☐    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
    (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)    ☐    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
    (k)    ☐    Group, in accordance with §240.13d-(b)(1)(ii)(K).

    Not applicable.

     

    Item 4.

    Ownership.

    The aggregate ownership percentage of shares of the issuer’s common stock owned by each person named in this Schedule 13G is based upon 112,126,549 shares of the issuer’s common stock outstanding as reported in the issuer’s Form 10-Q quarterly report for the fiscal quarter ended September 30, 2021. Seamark Capital, L.P., and John D. Fraser, Co-Managing Partner, and David T. Harrington, Co-Managing Partner, are beneficial holders in the aggregate of 7,014,162 shares of issuer’s common stock. In so much as Messrs. Fraser and Harrington serve as co-portfolio managers of Seamark Capital’s advisory client, the Seamark Fund, L.P., the parties may be deemed to collectively represent a group with respect to voting rights and dispositive rights. Investment decisions for Seamark Capital are made solely through the Co-Managing Partners, who individually also make investment decisions for each of their own respective direct holdings.

     

      (a)

    Amount beneficially owned:

     

      (1)

    5,558,966 shares

      (2)

    525,196 shares

      (3)

    930,000 shares

    Note: To the extent of Messrs. Fraser and Harrington’s interests in Seamark Capital’s investment vehicles, they may be deemed to be beneficial owners of additional shares beyond direct holdings.


    Schedule 13G    Page 7

     

    CUSIP NO. 04537Y109

      

     

      (b)

    Percent of Class:

     

      (1)

    5.0%

      (2)

    0.5%

      (3)

    0.8%

    TOTAL: 6.3%

     

      (c)

    Number of Shares as to which the person has:

     

      i.

    Sole power to vote or to direct the vote:

     

      (1)

    0 shares

      (2)

    525,196 shares

      (3)

    930,000 shares

     

      ii.

    Shared power to vote or to direct the vote:

     

      (1)

    5,558,966 shares

      (2)

    6,084,162 shares

      (3)

    6,488,966 shares

     

      iii.

    Sole power to dispose or to direct the disposition of:

     

      (1)

    0 shares

      (2)

    525,196 shares

      (3)

    930,000 shares

     

      iv.

    Shared power to dispose or to direct the disposition of:

     

      (1)

    5,558,966 shares

      (2)

    6,084,162 shares

      (3)

    6,488,966 shares

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.  ☐

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.


    Schedule 13G    Page 8

     

    CUSIP NO. 04537Y109

      

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    Schedule 13G    Page 9

     

    CUSIP NO. 04537Y109

      

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

          SEAMARK CAPITAL, L.P., by its General Partner,
          SEAMARK PARTNERS, L.P., by its General Partners
    Date: February 15, 2022       By:   

    /s/ John D. Fraser

             John D. Fraser,
             Partner
    Date: February 15, 2022       By:   

    /s/ David T. Harrington

             David T. Harrington,
             Partner
    Date: February 15, 2022         

    /s/ John D. Fraser

             John D. Fraser
    Date: February 15, 2022         

    /s/ David T. Harrington

             David T. Harrington


    Schedule 13G    Page 10

     

    CUSIP NO. 04537Y109

      

     

    JOINT FILING AGREEMENT

    The undersigned, the Reporting Persons named in this Amendment No. 3 to Schedule 13G (the “Schedule 13G”), hereby agree that the Schedule 13G is filed on behalf of each of them and that each Reporting Person is responsible for the timely filing of any amendments to the Schedule 13G. Each Reporting Person further agrees that each of them is responsible for the completeness and accuracy of the information concerning such Reporting Person, respectively, contained in the Schedule 13G and that each of them is not responsible for the completeness or accuracy of the information concerning the other Reporting Persons.

    IN WITNESS WHEREOF, the undersigned have executed this Joint Filing Agreement as of the 15th day of February, 2022.

     

    SEAMARK CAPITAL, L.P., by its General Partner, SEAMARK PARTNERS, L.P., by its General Partners
    By:  

    /s/ John D. Fraser

      John D. Fraser,
      Partner
    By:  

    /s/ David T. Harrington

      David T. Harrington,
      Partner

    /s/ John D. Fraser

    John D. Fraser

    /s/ David T. Harrington

    David T. Harrington
    Get the next $AWH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AWH

    DatePrice TargetRatingAnalyst
    1/12/2022$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AWH
    Leadership Updates

    Live Leadership Updates

    See more
    • Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

      AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

      12/16/24 8:45:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Selected as a Spoke for the Investor Catalyst Hub

      AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of

      9/5/24 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Appoints Mr. John Ragard to its Board of Directors

      AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is an accomplished executive with extensive experience successfully managing several billion-dollar portfolios over his career. "We are pleased to welcome John to our Board of Directors," said Ms. Jannie Herchuk, Chairwoman of the Board at Aspira Women's Health. "John brings a wealth of experience and a keen understanding of Wall Street, having been a successful money manager for the past

      7/29/24 9:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Aspira Women's Health with a new price target

      Cantor Fitzgerald resumed coverage of Aspira Women's Health with a rating of Overweight and set a new price target of $4.00

      1/12/22 7:53:25 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Truist Securities initiated coverage on Aspira Womens Health with a new price target

      Truist Securities initiated coverage of Aspira Womens Health with a rating of Buy and set a new price target of $12.00

      3/29/21 7:32:28 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cantor Fitzgerald initiated coverage on Aspira Womens Health with a new price target

      Cantor Fitzgerald initiated coverage of Aspira Womens Health with a rating of Overweight and set a new price target of $10.00

      1/29/21 6:12:39 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    SEC Filings

    See more

    $AWH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AWH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amendment: SEC Form S-1/A filed by Aspira Women's Health Inc.

      S-1/A - Aspira Women's Health Inc. (0000926617) (Filer)

      4/30/25 8:10:19 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEFR14A filed by Aspira Women's Health Inc.

      DEFR14A - Aspira Women's Health Inc. (0000926617) (Filer)

      4/22/25 4:05:41 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Aspira Women's Health Inc. (0000926617) (Filer)

      4/16/25 5:07:30 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • New insider Fraser John D claimed ownership of 841,558 shares (SEC Form 3)

      3 - Aspira Women's Health Inc. (0000926617) (Issuer)

      4/28/25 7:19:40 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Hundorfean Cynthia D

      3 - Aspira Women's Health Inc. (0000926617) (Issuer)

      4/24/25 9:41:23 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Vos Ellen O'Connor converted options into 5,313 shares, increasing direct ownership by 8% to 68,677 units (SEC Form 4)

      4 - Aspira Women's Health Inc. (0000926617) (Issuer)

      4/2/25 8:23:47 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

      Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations.Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and established businesses. He brings hands-on leadership experience in clinical diagnostics specializing in precision medicine and patient outcomes in oncology, rare dise

      1/10/25 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

      AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

      12/16/24 8:45:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award

      AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result, Aspira has received a $2 million cash payment under the terms of the related agreement. ARPA-H's Sprint for Women's Health was created to address critical unmet challenges in women's health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. As previously a

      12/3/24 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Schuler Jack W bought 6,536 shares (SEC Form 4)

      4 - Aspira Women's Health Inc. (0000926617) (Issuer)

      7/11/24 5:15:45 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Schuler Jack W bought 28,500 shares (SEC Form 4)

      4 - Aspira Women's Health Inc. (0000926617) (Issuer)

      6/18/24 4:12:21 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Sandford Nicole bought $22,973 worth of shares (9,493 units at $2.42), increasing direct ownership by 16% to 70,596 units (SEC Form 4)

      4 - Aspira Women's Health Inc. (0000926617) (Issuer)

      6/3/24 5:30:57 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aspira Women's Health Inc.

      SC 13G - Aspira Women's Health Inc. (0000926617) (Subject)

      11/14/24 3:23:57 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aspira Women's Health Inc.

      SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)

      7/11/24 5:14:26 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aspira Women's Health Inc.

      SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)

      6/18/24 4:13:01 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Financials

    Live finance-specific insights

    See more
    • Aspira Women's Health Reports Selected Third Quarter 2024 Financial Results

      Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. "OvaWatch® product volume, which we believe is the most import

      11/14/24 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

      AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows: Conference Call & Webcast Details:Date:Thursday, November 14, 2024Time:8:30 am ETToll Free:877-545-0320International:973-528-0002Access Code:436613Webcast:R

      11/4/24 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12

      AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date: Monday, August 12, 2024Time: 4:30 p.m. ETToll Free:877-407-4018Webcast:Click HERE   A replay of the webcast will also be

      7/31/24 4:05:00 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care